4D Molecular Therapeutics
California, United States · Biotechnology, Genetics, Health Care
4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Pha
Key facts
- Headquarters
- California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (FDMT)
- Website
- 4dmoleculartherapeutics.com
- Company page
Recent activity at 4D Molecular Therapeutics
- : SEC 8-K (8.01): On September 28, 2026, 4D Molecular Therapeutics, Inc. announced the enrollment of the first patients in its Phase 3 clinical trial called 4SIGHT, which evaluates the efficacy of 4D-150 for treating diabetic macular edema (DME). The trial involves 514 treatment-naïve patients and is designed to compare the mean change in best corrected visual acuity at Week 52 between the 4D-150 treatment and an aflibercept comparator. Additionally, the Company shared 2-year data from the previous SPECTRA clinical trial, indicating a continuous commitment to advancing its clinical research in ocular diseases. This trial is significant for the company’s portfolio and could impact its future market positioning and financial performance in the field of innovative therapies for eye conditions.
- : 4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer
- : 4D Molecular Therapeutics Enters Licensing Agreement with Otsuka Pharmaceutical
- : SEC 8-K (1.01): On October 31, 2025, 4D Molecular Therapeutics, Inc. entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. This agreement grants Otsuka exclusive rights to develop and commercialize 4D-150 for treating ophthalmological diseases such as wet AMD and DME across Japan, China, Australia, and other Asia-Pacific markets. Otsuka will handle all regulatory and commercialization efforts in these regions, while 4D Molecular Therapeutics will continue to manage Phase 3 clinical activities globally, with plans to open APAC clinical sites for their Phase 3 study in wet AMD by the end of 2025, and Japan sites expected to launch in January 2026. This collaboration positions both companies to strategically enhance their market presence in key Asian territories.
- : 4D Molecular Therapeutics Shares Promising Results from Phase 2b PRISM Wet AMD Study for Product 4D-150.
- : 4DMT Appoints Uneek Mehra as Chief Financial and Business
- : 4D Molecular Therapeutics Inc
- : 4D Molecular Therapeutics Inc
- : 4D Molecular Therapeutics Inc
4D Molecular Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2018 | Venture | $90.0M |
| Oct 2015 | Venture | $11.6M |
| Aug 2015 | Venture | $7.0M |
Leadership
- Tony Yao, Director
- Charles Ph.D., Director
- David Ph.D.,, Executive Officer, Director
- Margi McLaughlin, Director
- Hoyoung Ph.D., Director
- David M.D., Executive Officer, Director
- Dhaval B. Desai, Chief Development Officer
- David Kirn, Founder
- Kristian Humer, Chief Financial Officer
- David Kirn, Chief Executive Officer
- Kristine Leaños, Employee Development and Relationship Building
- Jelica Stulic
Verified email and direct lines for 4D Molecular Therapeutics’s decision-makers are on Fundz. See plans
4D Molecular Therapeutics in the news
- 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD - GlobeNewswire (Jun 29, 2026)
- 4DMT presents positive interim data from Phase 2 PRISM clinical trial of intravitreal 4D-150 for wet AMD - Ophthalmology Times (Feb 05, 2024)
- Arshad Khanani, MD, on Comparing Wet AMD Gene Therapy 4D-150 to Aflibercept in a Randomized Clinical Trial - CGTLive® (Mar 11, 2024)
- 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - GlobeNewswire (Jun 29, 2026)
- Reshaping Retinal Care With Gene Therapy Programs, With Christina Y. Weng, MD - HCPLive (Apr 25, 2025)
- Strategies of AAV capsid engineering for targeted delivery to brain, muscle, and retina - frontiersin.org (Jan 06, 2026)
- The gene therapy shift - Ophthalmology Times (Feb 16, 2026)
- Gene Therapy Restores Aflibercept Expression in Wet AMD - CGTLive® (Nov 15, 2022)
Companies similar to 4D Molecular Therapeutics
- Elevation Oncology · Biotechnology, Genetics, Health Care, Medical, Therapeutics
- Modalis Therapeutics Corporation · Biotechnology, Genetics, Health Care, Medical, Therapeutics
- Agendia · Biotechnology, Genetics, Health Care, Medical, Therapeutics
- Vico Therapeutics · Biotechnology, Genetics, Health Care, Medical, Therapeutics
- BioMarin · Biotechnology, Genetics, Health Care, Medical, Therapeutics
About 4D Molecular Therapeutics: questions and answers
What does 4D Molecular Therapeutics do?
4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Pha
Where is 4D Molecular Therapeutics headquartered?
4D Molecular Therapeutics is headquartered in California, United States.
Has 4D Molecular Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for 4D Molecular Therapeutics. The most recent, $90.0M, was in Sep 2018.
Who leads 4D Molecular Therapeutics?
David Kirn is a Founder at 4D Molecular Therapeutics.
What is the latest news on 4D Molecular Therapeutics?
On Sep 28, 2026, SEC 8-K (8.01): On September 28, 2026, 4D Molecular Therapeutics, Inc. announced the enrollment of the first patients in its Phase 3 clinical trial called 4SIGHT, which evaluates the efficacy of 4D-150 for treating diabetic macular edema (DME). The trial involves 514 treatment-naïve patients and is
Is 4D Molecular Therapeutics a public company?
Yes. 4D Molecular Therapeutics is publicly traded under the ticker FDMT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy